Abstract OT1-08-02: TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242)

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Locally Recurrent ◽

Randomized Phase 2 ◽

COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1100 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1100-TPS1100 ◽

Cited By ~ 1

Author(s):

David Miles ◽

Sung-Bae Kim ◽

V. A. McNally ◽

Brian P. Simmons ◽

Matthew Wongchenko ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Safety And Efficacy ◽

Phase 2 Study ◽

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz242.076 ◽

2019 ◽

Vol 30 ◽

pp. v138

Author(s):

A.H. Awada ◽

J. Cortés ◽

S. Slater ◽

I. Macpherson ◽

T. Csoszi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Locally Recurrent ◽

Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1106 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1106-TPS1106

Author(s):

Denise A. Yardley ◽

Javier Cortes ◽

Robert E. Coleman ◽

Pier Franco Conte ◽

Adam Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Abstract P5-15-03:nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

10.1158/1538-7445.sabcs16-p5-15-03 ◽

2017 ◽

Cited By ~ 6

Author(s):

D Yardley ◽

R Coleman ◽

P Conte ◽

J Cortes ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Randomized Phase 2 ◽

Abstract OT1-03-18: COLET: A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib in combination with paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs15-ot1-03-18 ◽

2016 ◽

Author(s):

S-B Kim ◽

D Miles ◽

J Rhee ◽

Y Yan ◽

J Hsu ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.1074 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1074-1074

Author(s):

Adam Brufsky ◽

Sung-Bae Kim ◽

Thierry J. Velu ◽

Jose Angel Garcia Saenz ◽

Elizabeth Tan-Chiu ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

First Line Treatment ◽

Biomarker Data

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study

Chemotherapy ◽

10.1159/000356156 ◽

2013 ◽

Vol 59 (3) ◽

pp. 207-213 ◽

Cited By ~ 4

Author(s):

Yuqian Liao ◽

Ying Fan ◽

Yiye Wan ◽

Jun Li ◽

Lixiang Peng

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Limited Efficacy ◽

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz100.047 ◽

2019 ◽

Vol 30 ◽

pp. iii63

Author(s):

V. Boni ◽

C. Alemany ◽

J.L. Meisel ◽

R. Sinha ◽

D. Sterrenberg ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Open Label Phase ◽